William Blair Comments on Nkarta’s Q2 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Equities researchers at William Blair reduced their Q2 2025 EPS estimates for Nkarta in a research report issued on Thursday, May 15th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.50) per share for the quarter, down from their previous forecast of ($0.45). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.95) EPS.

Several other brokerages also recently issued reports on NKTX. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus lowered their price target on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. Finally, Needham & Company LLC lowered their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Nkarta has an average rating of “Buy” and an average target price of $14.67.

Nkarta Price Performance

Shares of Nkarta stock opened at $1.74 on Monday. The firm has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $2.19. The company has a market cap of $123.47 million, a PE ratio of -0.93 and a beta of 0.81. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $8.23.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. acquired a new position in Nkarta during the fourth quarter valued at approximately $30,000. Sequoia Financial Advisors LLC acquired a new position in Nkarta during the fourth quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new position in Nkarta during the fourth quarter valued at approximately $37,000. Wealth Enhancement Advisory Services LLC acquired a new position in Nkarta during the first quarter valued at approximately $32,000. Finally, ProShare Advisors LLC acquired a new position in Nkarta during the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.